Dual Antiplatelet Therapy Beyond 12 Months Versus for 12 Months After Drug-Eluting Stents for Acute Myocardial Infarction
- Doo Sun Sim; Myung Ho Jeong; Hyo Soo Kim; Hyeon Cheol Gwon; Ki Bae Seung; Seung Woon Rha; Shung Chull Chae; Chong Jin Kim; Kwang Soo Cha; Jong Seon Park; Jung Han Yoon; Jei Keon Chae; Seung Jae Joo; Dong Ju Choi; Seung Ho Hur; In Whan Seong; Myeong Chan Cho; Doo Il Kim; Seok Kyu Oh; Tae Hoon Ahn; Jin Yong Hwang
- Dept. of Internal Medicine (내과학)
- Issue Date
- Journal of cardiology, Vol.75(1) : 66-73, 2020
The optimal duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome remains uncertain. This study investigated the benefit of DAPT beyond 12 months after drug-eluting stents (DES) for acute myocardial infarction (MI).
From Korea Acute Myocardial Infarction Registry-National Institute of Health database, 6199 patients treated with DAPT for 12 months after DES (second-generation DES 98%) without ischemic or bleeding events were analyzed. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), a composite of death from any cause, MI, or ischemic stroke during the period from 12 to 24 months.
After adjustment using inverse probability of treatment weighting, patients who received DAPT beyond 12 months ( n = 4795), compared to patients treated with 12-month DAPT ( n = 1404), had a similar incidence of MACCE (1.3% vs. 1.0%, HR: 1.32, 95% CI: 0.71–2.45, p = 0.378). The 2 groups did not differ significantly in the rates of death (0.1% vs. 0.1%), MI (0.8% vs.0.6%), stent thrombosis (0.1% vs. 0.2%), ischemic stroke (0.4% vs. 0.2%), and major bleeding (0.1% vs. 0.1%). The rate of net adverse clinical events was 1.4% with DAPT beyond 12 months and 1.1% with 12-month DAPT ( p = 0.466).
DAPT beyond 12 months, as compared with 12-month DAPT, in real-world patients with acute MI treated predominantly with second-generation DES did not reduce the risk of MACCE. The rates of major bleeding and net adverse clinical events did not differ significantly between the 2 treatments.
- Antiplatelet agents; Drug-eluting stents; Myocardial infarction
- Appears in Collections:
- 1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
- Keimyung Author(s)
- Full Text
- File in this Item
- RIS (EndNote)
- XLS (Excel)